Operetta 2 is a clinical research study for children and teenagers living with Relapsing-Remitting Multiple Sclerosis (RRMS). The study will look at the effects, good or bad, of Ocrelizumab to understand if it can help treat RRMS in children and teenagers.
Operetta 2 is sponsored by Hoffmann-La Roche. The study is utilizing the c4c network to support the running of the study.
Participating centers in the Netherlands: Erasmus MC.
Interested to find out more? Please visit the Operetta 2 website or clinicaltrials.gov